After a disappointing year for pharmaceutical companies, the Vioxx heat thrown on the FDA, and the withdrawal of Biogen Idec Inc.'s Tysabri, dissecting the drug development model and insinuating pharmacogenomics into it not only is timely, but appropriate.
After a disappointing year for pharmaceutical companies, the Vioxx heat thrown on the FDA, and the withdrawal of Biogen Idec Inc.'s Tysabri, dissecting the drug development model and insinuating pharmacogenomics into it not only is timely, but appropriate.
